The Forge clients Hyivy Health, PROVA Innovations, and Tenomix have been accepted to Hamilton Ecosystem to Accelerate & Leverage Trials of Health Innovation – HEALTHI, a funding program in collaboration with the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP), Innovation Factory and the Synapse Consortium. The life science companies will be able to leverage up to $15,000 in funding from NRC-IRAP to work directly with the Research Administration groups at Hamilton Health Sciences or The Research Institute at St. Joe’s Hamilton to create pre-trial protocols and documents required to undertake a commercialization project or clinical trial.
Hyivy Health creates an intelligent and holistic pelvic rehabilitation device for women who experience pelvic health complications. The innovative device provides a quantifiable data set on the pelvic floor and three different therapies from multiple sensors and mechanical functions to help measure progress, adapt treatment plans and provide more effective, comfortable rehab experiences. Hyivy Health is launching a research study with Hamilton Health Sciences to measure the effects of chronic pelvic pain for women with endometriosis.
PROVA Innovations specializes in wearable technology solutions for in-home GAIT training and neuromuscular rehabilitation for patients with brain injury, neurological disorder, degenerative disease, or a mobility challenge. Its products uniquely promote exercise and neuro recovery in a non-invasive way by providing the patient with consistent biofeedback and coaching during everyday activities. In partnership with St. Joseph’s Healthcare Hamilton, PROVA Innovations’ goals include preparatory work for clinical study and evaluation, engagement with key stakeholders and decision-makers through planned focus groups, and identifying potential collaborative funding avenues to finance upcoming clinical trials.
Tenomix is a medical technology company creating innovative solutions in pathology. Tenomix, in collaboration with Hamilton Health Sciences, will engage with pathology staff for early prototype feedback, as well as the development of a clinical study protocol.